Page last updated: 2024-10-15

bemotrizinol

Cross-References

ID SourceID
PubMed CID135487856
CHEMBL ID2104956
CHEBI ID135857
SCHEMBL ID77320
SCHEMBL ID649229
MeSH IDM000601427

Synonyms (64)

Synonym
tinosorb s (tn)
bemotrizinol (usan/inn)
187393-00-6
D03227
phenol, 2,2'-(6-(4-methoxyphenyl)-1,3,5-triazine-2,4-diyl)bis(5-((2-ethylhexyl)oxy)-
bemt
fat 70'884
bemotrizinol
bemotrizinol [usan]
tinosorb s
2,2'-(6-(4-methoxyphenyl)-1,3,5-triazine-2,4-diyl)bis(5-((2-ethylhexyl)oxy)phenol)
bis-ethylhexyloxyphenol methoxyphenyl triazine ,
CHEBI:135857
HMS3264F07
nsc-759870
nsc759870
pharmakon1600-01503863
CHEMBL2104956
fat-70884
unii-pwz1720cbh
bemotrizinol [usan:inn]
tinosorb s aqua
pwz1720cbh ,
cgf 1607
nsc 759870
phenol,2,2'-[6-(4-methoxyphenyl)-1,3,5-triazine-2,4-diyl]bis[5-[(2-ethylhexyl)oxy]-
AM84647
2,2'-[6-(4-methoxyphenyl)-1,3,5-triazine-2,4-diyl]bis{5-[(2-ethylhexyl)oxy]phenol}
bemotrizinol [usp-rs]
bemotrizinol [inn]
bemotrizinol [mart.]
bemotrizinol [who-dd]
bemotrizinol [mi]
bis-ethylhexyloxyphenol methoxyphenyl triazine [inci]
SCHEMBL77320
SCHEMBL649229
NCGC00261970-01
AB01563045_01
J-506774
bemotrizinol, analytical standard
bemotrizinol, united states pharmacopeia (usp) reference standard
2,4-bis[4-(2-ethylhexyloxy)-2-hydroxyphenyl]-6-(4-methoxyphenyl)-1,3,5-triazine
XVAMCHGMPYWHNL-UHFFFAOYSA-N
AS-73952
F20693
5-[(2-ethylhexyl)oxy]-2-(4-{4-[(2-ethylhexyl)oxy]-2-hydroxyphenyl}-6-(4-methoxyphenyl)-1,3,5-triazin-2-yl)phenol
AKOS030621549
6,6'-(6-(4-methoxyphenyl)-1,3,5-triazine-2,4-diyl)bis(3-((2-ethylhexyl)oxy)phenol)
ZB0626
DTXSID40896984
Q4885134
SY041028
mfcd08435974
DB11206
BCP20168
bemt; bis-ethylhexyloxyphenol methoxyphenyl triazine; tinosorb s
bemotrizinol ;cgf 1607
5-(2-ethylhexoxy)-2-[4-[4-(2-ethylhexoxy)-2-hydroxyphenyl]-6-(4-methoxyphenyl)-1,3,5-triazin-2-yl]phenol
2,4-bis[4-(2-ethylhexyloxy)-2-hydroxyphenyl]-6-(4-methoxyphenyl)-1,3,5-triazine (bemotrizinol)
A907647
CS-0152372
HY-W099730
EN300-23553143
B6145

Pharmacokinetics

ExcerptReference
" An in vitro skin permeation test (IVPT) and clinical pilot pharmacokinetic Maximum Usage Trial (MUsT) were completed to support the GRASE determination for 6% BEMT."( Preliminary clinical pharmacokinetic evaluation of bemotrizinol - A new sunscreen active ingredient being considered for inclusion under FDA's over-the-counter (OTC) sunscreen monograph.
D'Ruiz, CD; Erato, C; Hammonds, J; Klock, J; Mesaros, S; Plautz, JR; Sanabria, C; Schuetz, R; Vollhardt, J, 2023
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
methoxybenzenesAny aromatic ether that consists of a benzene skeleton substituted with one or more methoxy groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency3.98110.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (25.00)29.6817
2010's10 (41.67)24.3611
2020's8 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (11.54%)5.53%
Reviews1 (3.85%)6.00%
Case Studies1 (3.85%)4.05%
Observational0 (0.00%)0.25%
Other21 (80.77%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]